[Targeting epidermal growth factor receptor in non-small cell lung cancer: current advances and perspectives].

Abstract excerpt

EGFR tyrosine kinase inhibitors are currently included in the therapeutic armamentarium against advanced NSCLC. However, many questions on the use of anti-EGFR treatment in NSCLC still remain to be answered. Although several biological factors that may help identify those who are likely to respond to EGFR-targeted therapies have been reported, their clinical utility in routine practice remains to be determined....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antibodies, Monoclonal
• Share to Antibodies, Monoclonal, Humanized